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Translational relevance: 
ERBB2 (HER2) amplification is an emerging biomarker in colon cancer that confers sensitivity to 
combination anti-HER2 therapy and predicts resistance to anti-EGFR treatment. Measurement 
of HER2 copy number is typically performed using tissue obtained from surgical specimen or 
diagnostic biopsies, but with the advent of cell-free circulating tumor DNA (ctDNA) analysis, this 
information can also be obtained quickly and non-invasively when tissue is not available, while 
capturing the spatial and termporal tumor heterogeneity often present in treatment refractory 
patients. Herein, we present accurate determination of ERBB2 copy number in ctDNA. We 
describe a clinically validated ctDNA assay as a reliable diagnostic of ERBB2 copy number in 
plasma that predicted response rates to trastuzumab and lapatinib in a mCRC cohort similar to 
tissue-based HER2 protein expression. We also determined a plasma ERBB2 copy number 
cutoff, corrected for tumor shedding, that is predictive of anti-HER2 treatment response. 
 
Abstract 
Purpose: 
ERBB2 (HER2) amplification is an emerging biomarker in colon cancer, conferring sensitivity to 
combination anti-HER2 therapy. Measurement of HER2 copy number is typically performed 
using surgical specimens, but cell-free circulating tumor DNA (ctDNA) analysis may be a non-
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invasive alternative. We determined the sensitivity of pCN for detecting ERBB2 amplifications 
and whether plasma copy number (pCN) correlated with tissue-detected copy number. We also 
assessed response to HER2-targeted therapy based on pCN and suggest a pCN threshold 
predictive of response.  
 
Experimental Design: 
Forty-eight pre-treatment and progression plasma samples from 29 HER2-positive patients in 
the HERACLES A clinical trial were tested using the Guardant360™ cfDNA assay. We 
correlated ERRB2 pCN with progression-free survival (PFS) and best objective response (BOR) 
and applied an adjustment method based on tumor DNA shedding using the maximum mutant 
allele fraction as a surrogate for tumor content to accurately determine the pCN threshold 
predictive of response. 
 
Results: 
47/48 samples had detectable ctDNA and 46/47 samples were ERBB2-amplified based on 
cfDNA (2.55-122 copies; 97.9% sensitivity (95% CI = 87.2-99.8%). An adjusted ERBB2 pCN 
of >25.82 copies correlated with BOR and PFS (p=0.0347). 
 
Conclusions: 
cfDNA is a viable alternative to tissue-based genotyping in the metastatic setting. The cfDNA 
platform utilized correctly identified 28/29 (96.6%) of pre-treatment samples as ERBB2-amplified 
and predicted benefit from HER2-targeted therapy. In this study, an observed pCN of 2.4 and an 
adjusted pCN of 25.82 copies of ERBB2 is proposed to select patients who will benefit from 
HER2-targeted therapy. 
 
Introduction 
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Colon cancer is the 3rd most common cancer worldwide, and approximately 20% of patients 
present with metastatic disease (mCRC), which is associated with a poor prognosis and median 
overall survival (OS) of 24–30 months (1). Use of the anti-EGFR monoclonal antibodies 
cetuximab and panitumumab has improved progression-free survival (PFS) and OS in patients 
who are negative for KRAS, NRAS and BRAF mutations; however, these therapies are 
inevitably followed by disease progression (2). 
 
Very few effective therapies remain for the majority of patients with mCRC tumors that have 
become resistant to cetuximab or panitumimab (3). Amplification of ERBB2 (HER2) is an 
emerging biomarker present in 3-5% of genetically unselected mCRC and is enriched in 
RAS/RAF/PIK3CA-wildtype tumors (4,5). Several pre-clinical studies have also suggested that 
ERBB2 copy number gain it is a negative predictor of response to anti-EGFR therapy (4,6–8). 
 
Two studies have assessed the feasibility of targeting ERBB2 amplification in mCRC patients. 
HERACLES A was an open-label, phase 2 trial of trastuzumab and lapatinib in chemotherapy 
and EGFR antibody-refractory, HER2-positive patients and showed an objective response rate 
(ORR) of 30% (95% CI 14–50) and a disease control rate (DCR) of 59% (95% CI 39%-78%) 
compared to a 41.9% DCR associated with standard-of-care therapy (9–11). More recently, the 
MyPathways open-label phase 2 basket trial showed a 38% (95% CI 23%-55%) ORR using 
pertuzumab and trastuzumab in the same population (12). These studies confirmed HER2 as an 
important driver of mCRC and a successfull therapeutic target in EGFR antibody- and 
chemotherapy-refractory disease. 
 
HER2 over-expression and/or amplification can be assessed using a variety of tissue-based 
approaches, including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), 
PCR, or next generation sequencing (NGS). Non-invasive methods are also possible and 
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include assessment of HER2 over-expression in circulating tumor cells (CTCs) or measurement 
of ERBB2 copy number via next generation sequencing (NGS) of cell-free DNA (cfDNA).  
Although, tissue copy number (tCN) appears to predict benefit from HER2 inhibition (10) no data 
exists regarding use of cfDNA to predict this benefit in mCRC.   
 
Measurement of copy number using cfDNA is challenging due to the overwhelming excess of 
diploid leukocyte-derived DNA relative to the very small amount of tumor DNA in the cell-free 
compartment, even in individuals with metastatic disease who typically have a large tumor 
burden. A recent study of cfDNA analysis in >21,000 individuals with metastatic solid tumors 
showed a median mutant allele fraction of only ~0.4%, which is equivalent to 4 mutant 
molecules for every 1000 total (mutant and wild-type) molecules, and a median copy number for 
gene amplifications of 2.56 (13). Therefore, any cfDNA assay utilized for clinical genotyping 
must be highly sensitive while maintaining high specificity. Furthermore, if the observed copy 
number in the tumor is low to moderate, even a tumor shedding large amounts of cfDNA into 
circulation may not yield detectable elevations in plasma copy number (pCN). In this context, as 
the plasma copy number in plasma is driven not only by tissue copy number but also by the 
extent of tumor DNA shedding, distinguishing between genomic characteristics, tumor burden, 
tumor proclivity to shed DNA, and tumor volume changes during therapy remains daunting. 
Finally, clinical specificity can also be a challenge, as copy number gains in tumor cells can be 
the result of focal gene amplification, which is often a viable target for drug therapy, or of 
amplification of large portions of a chromosome, which is less likely to associate with response 
to targeted therapy (14,15). To effectively identify candidate treatment targets, any assay must 
be able to discriminate between these two scenarios. Complicating assessment of cfDNA 
assays, direct comparisons to commonly utilized tissue-based approaches such as FISH and 
IHC are difficult, as differential shedding of tumor DNA into the circulation affects the pCN. 
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The goals of this study were: i.) to determine the sensitivity of ERBB2 amplification detection in 
plasma using a CLIA-certified, CAP-accredited cfDNA assay relative to standard tissue testing; 
ii.) to assess ERBB2 pCN as a predictor of HER2-targeted therapy benefit; and iii.) to establish 
a pCN threshold to enrich for patients potentially responsive to HER2-targeted. 
 
Materials and Methods 
HERACLES A patient cohort  
HERACLES A patients had a histologically confirmed diagnosis of metastatic colorectal cancer 
wild-type for KRAS exon 2 (codons 12 and 13) and positive for HER2 as defined by 3+ staining 
in >50% of cells by IHC or 2+ staining and a HER2:CEP17 ratio >2 in >50% of cells by FISH 
(14). Tissue samples for HER2 testing were derived from primary tumors for 11 (39%) of 28 
patients, from metastatic lesions for the remaining 17 (61%). The patient cohort is described in 
Table 1 and Figure 1. All had measurable disease according to Response Criteria Evaluation in 
Solid Tumors (RECIST) version 1.1. Patients received treatment and were assessed for 
objective response, PFS, best overall response and duration of response (11). As part of the 
trial, patients also underwent serial plasma collection for cfDNA analysis. Pre-treatment and at-
progression plasma samples (N=48; 29 pre-treatment and 19 at progression) from 29 HER2-
tissue positive patients were tested using the Guardant360® assay (Guardant Health, Inc. 
Redwood City, CA), and sensitivity was calculated. We also determined the observed ERBB2 
pCN cutoff that maximized the identification of the HERACLES A intent-to-treat population and 
best predicted response to trastuzumab plus lapatinib therapy. 
 
Guardant360 database and historical mCRC cohort 
ERBB2 amplification frequency, pCN distribution and RAS/RAF mutation co-occurrence were 
determined using the Guardant Health database (accessed April 11th, 2018). This cohort 
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comprised 4,294 plasma samples from individuals with stage III/IV colorectal cancer undergoing 
cfDNA analysis (Guardant360) as part of their routine care.  
 
cfDNA analysis  
cfDNA NGS analysis was performed at Guardant Health, Inc. (Guardant360; Redwood City, 
CA), a CLIA-certified, College of American Pathologists (CAP)-accredited, New York State 
Department of Health-approved laboratory (13,17). The Guardant360 assay detects single-
nucleotide variants (SNV), indels, fusions and copy number alterations in 73 genes with a 
reportable range of ≥0.04%, ≥0.02%, ≥0.04%, and ≥2.12 copies, respectively, as well as 
microsatellite instability (Supp. Fig. 1A). For the HERACLES A trial, 10ml of whole blood was 
collected in EDTA tubes. Plasma was separated within 5 hours of collection using 2 different 
centrifugation steps. Plasma was stored at -80°C until cfDNA extraction. cfDNA was extracted 
from 1-2 ml of plasma (QIAmp Circulating Nucleic Acid Kit, Qiagen, Inc.), labeled with non-
random oligonucleotide barcodes (IDT, Inc.) and used to prepare sequencing libraries, which 
were then enriched by hybrid capture (Agilent Technologies, Inc.), pooled, and sequenced by 
paired-end synthesis (NextSeq 500 and/or HiSeq 2500, Illumina, Inc.). Separate sequencing 
controls were utilized for SNVs and CNs/fusions/indels (CFI) (Supp. Fig. 1B). 
 
Bioinformatic analysis and observed copy number determination 
As previously described, base call files generated by Illumina’s RTA software (v2.12) were de-
multiplexed using bcl2fastq (v2.19) and processed with a custom pipeline for molecule barcode 
detection, sequencing adapter trimming, and base quality trimming (discarding bases below 
Q20 at the ends of the reads) (13). Processed reads were then aligned to hg19 using BWA-
MEM (arXiv:1303.3997v2) and used to build double-stranded consensus representations of 
original unique cfDNA molecules using both inferred molecular barcodes and read start/stop 
positions. To detect copy number amplification, probe-level unique molecule coverage was 
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normalized for overall unique molecule throughput, probe efficiency, GC content, and signal 
saturation and robustly summarized at the gene level. pCN determinations were based on 
training set-established decision thresholds for both observed copy number deviation from per-
sample diploid baseline and deviation from the baseline variation of probe-level normalized 
signal in the context of background variation within each sample’s own diploid baseline. Per-
sample relative tumor burden was determined by normalization to the mutational burden 
expected for tumor type and ctDNA fraction and reported as a z-score. Observed ERBB2 pCN 
values representing the lower 50th, 50th-90th, and the top 10th percentiles across all amplified 
samples in the Guardant Health database were calculated (13). 
 
Correlation between ISH, tissue copy number and calculation of an adjusted plasma copy 
number 
tCN in the HERACLES A trial was centrally determined using several methodologies including 
IHC, FISH and quantitative real-time PCR (qRT-PCR) (11). Observed pCN using cfDNA NGS 
was compared to FISH and qRT-PCR methods, and Spearman’s correlations were calculated. 
To correct for variation in plasma tumor fraction between samples that can affect the tumor 
contribution to the circulating DNA pool and consequenctly pCN, we adjusted the observed pCN 
to the proportion of tumor DNA in each cfDNA sample. To do this, we used the maximum 
mutant allele fraction (MAF%/100) observed in each individual sample as a surrogate for 
plasma tumor fraction (T%), as this typically represents the earliest initiating mutation shared by 
all tumor clones. Genes with the highest MAF were TP53 (n=15), APC (n=11), PTEN (n=1) and 
RAF1 (n=1) (Supp table 2).  We then calculated an adjusted pCN (ApCN); Adjusted pCN = 
[Observed pCN – 2*(1-T%)]/T% where T% = 2 X MAFmax/100. The methodology for calculating 
adjusted pCN was developed independently and outside of the context of current project and 
had been finalized prior to integration into the present study. 
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Clinical outcomes based on adjusted plasma copy number 
We correlated ApCN with PFS and best objective response (BOR) on trastuzumab and lapatinib 
and calculated significance using the Mantel-Cox test. We used ROC curve and optimal cutoff 
analysis to determine ApCN cutoffs with the highest sensitivity and specificity to predict 
response.  
 
All patients provided written informed consent. The study was done in accordance with the 
principles of the Declaration of Helsinki, the International Conference on Harmonization and 
Good Clinical Practice guidelines and the US Common Rule. The institutional review boards of 
the participating centres approved the study procedures. 
 
Results 
ERBB2 pCN and RAF/RAF status in the HERACLES A cohort 
Forty-eight banked plasma samples from 29 patients were available for analysis, including 29 
pre-treatment and 19 at-progression plasma samples. One at-progression sample had no 
detectable ctDNA, leaving 47 (29 pre-treatment and 18 post-treatment) evaluable samples. 
ERBB2 amplification was identified in 46 of 47 plasma samples (28/29 pre-treatment and 18/18 
at-progression) for a sensitivity of 97.9% (95% CI = 87.2-99.8%). The mean pCN in pre-
treatment samples was 23.1 copies (median = 9.28; range = 2.6-121.7 copies) and 16.76 
(median = 8.48; range = 2.13-82.17) in at-progression samples.  
 
To assess focal vs. non-focal amplification, we examined the copy number of genes neighboring 
ERBB2 on chromosome 17 to differentiate aneuploidy or large (e.g. arm-level) events. Only a 
single sample in this study demonstrated a pattern suggestive of a large-scale chromosome 17 
amplification event (Supp. Fig. 2A ). This patient had stable disease and progressed after 6 
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months of therapy. The remainder of samples showed patterns most compatible with focal 
amplification (Supp. Fig. 2B).   
 
Ten KRAS, NRAS, and BRAF mutations were identified in pre-treatment samples from 9 
patients. There were 3 RAS codon 12/13 mutations, 5 non-codon 12/13 mutations (4 KRAS and 
1 NRAS) and 3 BRAF mutations (V600E, G469A and G596R). BRAF G469A and KRAS Q61H 
co-occurred in one sample.  Three patients with primary resistance to therapy (n=1) or 
radiographic progression (n=2) had clonal RAS/RAF driver mutations as defined by a 
RAS/RAF:maximum allelic fraction ratio of >0.3 (Fig. 2) (18). 
 
ERBB2 amplification frequency in a historical ctDNA cohort 
There were 4,294 unique mCRC patients in the Guardant Health database tested between 
February 5th, 2015 and April 11th, 2018. Centiles of ERBB2 pCN were as follows: copy number 
2.4, 50th percentile; copy number 4, 90th percentile (Supp. Fig. 3). Of the 4,294 patients, 247 
(5.8%) had detectable ERBB2 amplification, which is compatible with previous reports of 
prevalence (4,16,19) An ERBB2 pCN cutoff of > 2.4 copies in the historical cohort allowed for 
exclusion of 84% of all KRAS, NRAS, and BRAF driver mutations in the historical cohort (Supp. 
Fig. 4) and suggest that samples with pCN above this threshold represent those for which 
ERBB2 amplification is the primary driver of malignancy. An observed pCN cutoff of 2.4 
accurately identified 100% of the intent to treat HERACLES A population (Fig. 2). 
 
Correlation between tissue copy number and observed and adjusted plasma copy number 
(ApCN) 
To determine the correlation between tCN and pCN, we compared ERBB2 observed pCN 
values with ISH and with tCN as measured by qRT-PCR. There was modest correlation 
between observed pCN and ISH (Spearman r = 0.49; Fig. 3A) and observed pCN and qRT-PCR 
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tCN (Spearman r=0.52; Fig. 3C). Compared with observed pCN, adjusted pCN (ApCN) showed 
stronger correlation with ISH and  ERBB2 pCN by qRT-PCR (Fig. 3B and 3D) with a Spearman 
R of 0.77 and 0.86, respectively.  
 
Response to therapy based on ApCN and co-occurring alterations 
Radiographic response was assessed in 26 patients with ERBB2 amplification detected in 
plasma to determine if ApCN correlated with BOR (Fig. 4). Two patients had early clinical 
progression and were not imaged. We determined an ERBB2 ApCN cutoff value of 25.82 for 
optimal segregation of responders versus non-responders using ROC analysis (Supp. Table 2). 
There were 6 patients with RECIST-defined progressive disease (PD) and 2 patients with 
clinical evidence of primary resistance to therapy for whom imaging was not available at the 
time of progression. Of these 8 cases, 6 had an ApCN below 25.82 and 2 had a pCN > 25.82 
(Supp. Table 2). In addition to a pCN below 25.83, 3 patients with progressive disease had 
clonal KRAS or BRAF mutations (KRAS G12V, G12D and BRAF V600E) identifed in plasma 
(Supp. Table 2). Twenty patients (20/28, 71%) had some degree of clinical benefit, including 13 
with stable disease, 6 partial response and 1 complete response. Thirteen of these 20 patients 
had a ApCN > 25.82. Of these 13 patients with a ApCN >25.82, 7 had their disease controlled 
by anti-HER2 treatment: 1 achieved a partial response and the remaining 6 had stable disease 
according to RECIST. We also assessed the correlation between ApCN and PFS. The median 
PFS in individuals with a ApCN < 25.82 was 14.8 weeks, as compared to 22.5 weeks in those 
with a ApCN > 25.82 (Mantel Cox p = 0.0347, Fig. 5).  
 
Discussion 
Non-invasive methods of comprehensive genomic profiling are becoming standard clinical 
practice because they provide rapid and accurate identification of clonal driver alterations and 
selection of appropriate targeted therapy and allow for serial assessment of clonal tumor 
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dynamics (20). In mCRC, HER2-targeted therapy is emerging as an active therapy, but it has 
not entered widespread use, in part, due to difficulties in identifying HER2-positive mCRC 
patients who are likely to experience clinical benefit (18). In this context, not all cfDNA assays 
are well-validated, and many have limitations around the types of alterations they can detect 
with high sensitivity and specificity (21). Similarly, attempts in mCRC to isolate circulating tumor 
cells have resulted in limited and mixed success (22). Therefore, we utilized a cfDNA NGS 
assay that has been extensively validated for all four major types of genomic alterations and 
microsatellite instability (13). Copy number amplification is a challenging alteration type to detect 
in cfDNA due to the high ratio of diploid leukocyte DNA to tumor DNA in circulation, which 
dilutes tumor copy number signals. In our analysis, the cfDNA assay utilized detected ERBB2 
amplification in 28 of 29 pre-treatment and 18 of 18 evaluable at-progression plasma samples 
from the HERACLES A cohort.  
 
In the present series we observed weak correlation between observed pCN and tCN using a 
variety of methods, including IHC, ISH and qRT-PCR. This is in part due to the fact that different 
methodologies are measuring different analytes (protein over-expression vs. number of gene 
copies) and are not all quantitative (IHC, ISH), which can make direct comparisons difficult. 
However, the major confounding factor when comparing blood and tissue methods of copy 
number assessment is the variation in the amount of tumor DNA shed into the bloodstream. 
Concordance between tissue and plasma is often high when two criteria are met: 1) the 
observed copy number in the tumor is high and 2) there is ample shedding of DNA into 
circulation, i.e. the tumor fraction in circulation is high. In addition, pCN represents a summary of 
all amplified lesions that may be shedding DNA into circulation. As a result, pCN may be 
impacted by the heterogeneity of actual copy number across tumor sites. These factors may 
limit the sensitivity of cfDNA assessment, and make comparison of copy number between tissue 
and plasma challenging. Furthermore, observed pCN is often misleadingly low in samples with 
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low tumor fraction, despite high tCN, which could prevent patients with true oncogenic driver 
amplifications from receiving appropriate targeted therapy. To overcome some of these 
technical barriers, we adjusted the observed pCN for the amount of tumor DNA shedding using 
the maximum mutant allele fraction as a surrogate for tumor content. The resulting adjusted 
plasma copy number (ApCN) correlated with tCN and response to therapy in our analysis.   
 
Our results demonstrate a correlation between PFS/BOR and level of ERBB2 amplification; 
however, not all patients with high ERBB2 pCN responded (Fig. 4). One patient (121024) 
showing progressive disease had ERBB2 ApCN of 27.38, but there were no co-occurring 
mutations present in the baseline sample to explain the lack of response. There were also 5 
patients with stable disease, 1 with an unconfirmed partial response and 1 with a partial 
response who exhibited plasma copy numbers below the cutoff. Some of these patients showed 
evidence of acquired resistance mutations at the time of progression. Resistance mechanisms 
and ctDNA dynamics over the course of treatment in the HERACLES cohort have been 
extensively studied and are described in detail elsewhere (18). Interestingly, 3 patients with 
either progressive disease or primary clinical progression harbored clonal KRAS (n=2) BRAF 
(n=1) mutations, as assessed by cfDNA analysis. Although the HERACLES A trial excluded 
patients with KRAS mutations in their diagnostic tissue in most cases (the treatment-naïve 
primary tumor), these RAS/RAF mutations presumably developed during the prior course of 
anti-EGFR therapy and dominated the original KRAS WT clonal populations under selective 
pressure. Screening for BRAF mutations was not required for entry into HERACLES A but is 
now part of the NCCN guidelines, given the 4-5% mutation frequency in mCRC and associated 
lack of response to anti-EGFR therapy (3).  
 
Several studies have discussed the utility of cfDNA in assessing copy number amplification. 
Liang et al. showed perfect concordance (n=7 of 7 patients) between tissue and plasma-
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identified ERBB2 CN in metastatic breast cancer patients (23). All 7 patients were given anti-
HER2 therapy, and 6 of the 7 had a clinical response to therapy, underscoring the therapeutic 
relevance of ERBB2 pCN assessment. Similarly, in two separate studies of untreated 
gastric/gastroesophogaeal cancer patients, high ERBB2 pCN was a positive predictor of patient 
response and plasma was able to capture copy number changes present in both the primary 
tumor and the metastases (24). These papers highlight the fact that pCN measurements, unlike 
tissue measurements, are often a summary of all shedding lesions and can be influenced by 
tissue heterogeneity. The HERACLES A study further highlights the benefits of cfDNA copy 
number analysis and underscores the ability of cfDNA to capture tumor heterogeneity in mCRC 
patients. This latter capability may be similarly important in mCRC as, despite high concordance 
for somatic mutations between primary tumors and metastases, there is significant discordance 
(6%-15%) for tissue-assessed ERBB2 copy number amplifications (25,26). 
 
Limitations of this study include the small sample size and the lack of HER2-negative patients in 
the HERACLES A cohort. While the latter prohibits calculation of specificity, positive predictive 
value and negative predictive value in this cohort, the specificity and positive predictive value of 
the copy number assessment method utilized here have been described elsewhere (13). In that 
study, analytic specificity was > 99.9% and PPV was 100% when compared to ddPCR of cell 
lines with known gene copy number status. Another possible limitation of the methods employed 
here is distinction between focal copy number amplification, which in the case of ERBB2 in 
mCRC, is a druggable target, as compared to aneuploidy, which may not always result in 
protein over-expression and thus may not always respond to targeted agents. Despite the clear 
pattern of focal amplification in this study and others (19), these results cannot be considered 
representative of focal vs. non-focal amplification rates in other contexts as these vary widely by 
chromosome, cancer type, and treatment context. Another limitation of the study is the lack of 
detailed clinical information on the historical ctDNA cohort. The ctDNA test utilized here is 
Research. 
on March 6, 2019. © 2019 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 26, 2019; DOI: 10.1158/1078-0432.CCR-18-3389 
 15 
performed in a large reference laboratory where details such as previous therapy and current 
therapy at the time of the blood draw, histology, stage of disease at diagnosis, previous 
genomic testing results, etc. are not typically provided by the ordering clinician. Therefore, 
although the historical cohort represents later stage mCRC patients, the cohort is likely 
heterogeneous in terms of previous and current therapy status and direct comparisons between 
this cohort and the HERACLES A cohort must be done with caution. Lastly, the pCN adjustment 
method utilized here remains exploratory in nature and has not been validated in a separate 
cohort. Although the correlation of adjusted pCN with both FISH and tCN as determined by 
qRT-PCR and PFS/BOR suggest that this is a robust correction method, further validation of the 
model is necessary in additional larger cohorts. Furthermore, the current adjustment method 
does not consider copy number amplification or loss of heterozygosity of the gene comprising 
the mutation with the maximum mutant allele fraction from which tumor fraction is inferred. In 
particular, loss of heterozygosity in TP53 or APC, which are often the mutations with the highest 
mutant allele fraction in mCRC samples, could result in an over-representation of mutant alleles 
in the cfDNA sample and therefore result in an overestimation of tumor fraction. Correction for 
this may provide more accurate estimates of tCN as reflected in the plasma and should be 
explored. 
 
ERBB2 amplification is an emerging therapeutic target in the mCRC setting and may also be a 
negative predictor of response to anti-EGFR therapy (4,7). In this series, comprehensive cfDNA 
NGS accurately identified ERBB2 amplification in 96.6% (28/29) of the intent-to-treat population, 
suggesting that ctDNA can be used as a surrogate for tissue especially in cases when archival 
tissue cannot be obtained in a timely manner and re-biopsy is not preferred. In an independent 
study (20), ERBB2 amplification was detected in 2 mCRC patients by both cfDNA profiling and 
chromogenic in situ hybridization, further attesting to the value of cfDNA analysis in capturing 
the tissue genomic make-up. Additional investigation is needed to determine if plasma CN can 
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replace tissue CN assessment. In addition, as previously described, the assay identified co-
occurring mutations in KRAS, BRAF and ERBB2 that were predictive of resistance to therapy 
(27). Furthermore, we describe an adjusted pCN threshold above which patients are more likely 
to respond to targeted therapy. These results support use of appropriately validated cfDNA tests 
as an alternative to tissue biopsy to identify individuals who may benefit from anti-HER2 
therapy. Additional prospective studies in larger cohorts are needed, particularly in treatment-
naïve mCRC patients where targeted therapy may be most efficacious. 
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Table 1. Patient characteristics 
  Characteristic N (28) 
Gender   
Male 
 
22 
Female   6 
Median age at enrollment 
 
63 yrs. (range 41-
86) 
Primary tumor site 
Rectum 
 
7 
Proximal colon 
 
5 
Distal colon   16 
HER2 IHC Score 
2+(FISH AMPLIFIED) 
 
6 
3+   22 
No. of previous lines therapy 
<3 
 
7 
>3   21 
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Figure legends 
Figure 1. Consort diagram showing the HERACLES A cohort and the subset of patients 
included in the present study. 
 
Figure 2. ERBB2 pCN, RAS/RAF status and maximum mutant allele fraction (Max MAF) in 
baseline plasma samples from the HERACLES A cohort. An observed pCN cutoff of 2.4 (>50th 
%ile) allowed for identification of the HERACLES A intent-to-treat population. Both clonal (dark 
blue) and sub-clonal (light blue) RAS/RAF mutations were identified in pre-treatment plasma 
samples. 
 
Figure 3. 
Correlation between HER2/ERBB2 status in tissue and ERBB2 status in plasma. Observed pCN 
does not correlate strongly with HER2 ISH status (3A) or ERBB2 copy number as measured by 
qRT-PCR (3C), but adjusted plasma copy number correlates well with ISH and ERBB2 copy 
number as measured by qRT-PCR (3B and 3D). 
 
Figure 4.  
Best objective response based on adjusted pCN in baseline HERACLES A samples. Bars show 
the change in target lesion size from baseline to first progression. Horizontal dotted lines 
correspond to a 20% increase in target lesion size from baseline (top line) and 30% decrease in 
target lesion size from baseline (bottom line). Red bars represent samples with an adjusted pCN 
(ApCN) > 25.82 and blue bars an ApCN of < 25.82. * indicates patients with clonal RAS/RAF 
mutation in baseline plasma samples. Arrows indicate two patients with primary clinical 
progression who did not undergo radiagraphic imaging. 
 
Figure 5. 
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Progression-free survival by adjusted pCN (ApCN). Red line shows patients with an ApCN > 
25.82 and the blue line patients with an ApCN of < 25.82.  
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